Segment reporting (Tables)

3 Months Ended

Nov. 30, 2024

Segment Reporting [Abstract]

Reconciliation of Operating Income (Loss) from Segments to Consolidated

The following table reflects results of operations of the Company’s reportable segments (in millions):

	Three months ended November 30,
	2024		2023
Sales:
U.S. Retail Pharmacy
Pharmacy	$	24,711	$	22,384
Retail	6,155		6,560
Total	$	30,866	$	28,944
International
Pharmacy	$	912	$	926
Retail	2,117		1,932
Wholesale	3,397		2,974
Total	$	6,425	$	5,832
U.S. Healthcare	$	2,172	$	1,931
Corporate and Other 1	$	(4)	$	—
Walgreens Boots Alliance, Inc.	$	39,459	$	36,707
Adjusted operating income:
U.S. Retail Pharmacy	$	441	$	694
International	168		142
U.S. Healthcare	25		(96)
Corporate and Other	(41)		(53)
Walgreens Boots Alliance, Inc.	$	593	$	687

1.Includes certain eliminations.

The following table reconciles adjusted operating income to operating loss (in millions):

	Three months ended November 30,
	2024		2023
Adjusted operating income (Non-GAAP measure)	$	593	$	687
Footprint optimization	(333)		—
Acquisition-related amortization	(269)		(275)
Acquisition and disposition-related costs	(104)		(163)
Adjustments to equity earnings in Cencora	(76)		(50)
Certain legal and regulatory accruals and settlements	(59)		(82)
LIFO provision	(12)		(48)
Transformational cost management	15		(109)
Operating loss (GAAP measure)	$	(245)	$	(39)